GSK Collaborates with Innovax to Evaluate a Vaccine Against COVID-19 Pandemic

 GSK Collaborates with Innovax to Evaluate a Vaccine Against COVID-19 Pandemic

GSK Collaborates with Innovax to Evaluate a Vaccine Against COVID-19 Pandemic

Shots:

  • The companies collaborated to assess recombinant protein-based COVID-19 XWG-03, being developed by Innovax with Xiamen University
  • GSK will provide Innovax access to its adjuvant system for preclinical evaluation of the COVID-19 XWG-03. GSK’s adjuvants are additives used in vaccines to boost the body’s immune response to the relevant threat
  • The COVID-19 XWG-03 is based on a series of truncated S (spike) proteins which will be screened during the pre-clinical testing and a lead candidate will be determined based on its immunogenicity. Additionally, in 2019, the companies collaborated to develop a vaccine for HPV to devise a successor to Cervarix

Click here ­to­ read full press release/ article | Ref: GSK | Image: Fortes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post